《公司業績》康諾亞-B(02162.HK)半年虧損擴大至36.28億元人民幣
康諾亞-B(02162.HK)公布截至今年6月底止中期業績,其他收入及收益2,142.5萬元人民幣(下同),按年升152.3%。虧損擴大至36.28億元,上年同期蝕3,548.6萬元;每股虧損54.08元。不派息。
目前,公司擁有的十種可進入臨床試驗申請及臨床階段的候選藥物處於內部研發階段,其中五種處於臨床階段,兩種已向國家藥監局提交臨床試驗申請並獲受理。
公司預期對候選藥物的生產需求將增加,計劃進一步擴大符合cGMP的合規生產能力,新商業規模生產設施一期預期於2022年開始營運,額外產能為16,000公升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.